RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Johnson & Johnson (JNJ) presented Phase 2b COPERNICUS study results at WCLC 2026, showing low rates of treatment-related events for RYBREVANT FASPRO (amivantamab) plus LAZCLUZE (lazertinib) in advanced NSCLC. Fewer than 1% of patients discontinued treatment at one year. The study supports the regimen's safety and tolerability, building on prior survival benefits.
How this was made
The 30-second read
Why it matters
The data could improve the commercial outlook for the regimen and support JNJ's oncology pipeline narrative.
Market read
First disclosure of favorable Phase 2b safety data for a novel subcutaneous NSCLC therapy, potentially influencing JNJ stock and the oncology sector.
What to watch
Long‑term efficacy and overall survival data are still pending; investors should watch for upcoming Phase 3 results.
Background
Johnson & Johnson announced Phase 2b COPERNICUS results for its subcutaneous RYBREVANT FASPRO plus LAZCLUZE regimen, emphasizing reduced adverse events compared with the intravenous formulation.
Ticker impact
Johnson & Johnson presented Phase 2b COPERNICUS trial data showing low rates of rash, VTE and administration‑related reactions for RYBREVANT FASPRO + LAZCLUZE in untreated EGFR‑mutated NSCLC.
Potential modest upside for JNJ as investors reassess the commercial potential of the subcutaneous combo.
First‑time disclosure of Phase 2b data with favorable safety outcomes; no prior public release, indicating new material information.
Market effects
Strengthens the subcutaneous EGFR‑targeted therapy niche and may pressure competitors in the NSCLC space.
Highlights Johnson & Johnson's innovation pipeline in the U.S. and Asian markets where EGFR‑mutated NSCLC prevalence is high.
Adds to the broader oncology drug development narrative, potentially influencing biotech valuations.
Counterpoint
Safety improvements may not translate into significant market share if pricing or reimbursement challenges persist.
Key entities
- CompanyJohnson & Johnson
Pharmaceutical and medical device conglomerate presenting the trial data.
- DrugRYBREVANT FASPRO
Subcutaneous bispecific antibody targeting EGFR and MET.
- DrugLAZCLUZE
EGFR inhibitor combined with RYBREVANT FASPRO.
